ArticleCancer immunology, immunotherapy : CII2023

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.

Marta Español-Rego et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.